Your browser doesn't support javascript.
loading
Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group.
Moore, Andrew S; Shaw, Peter J; Hallahan, Andrew R; Carter, Tina L; Kilo, Tatjana; Nivison-Smith, Ian; O'Brien, Tracey A; Tapp, Heather; Teague, Lochie; Wilson, Shaun R; Tiedemann, Karin.
Afiliação
  • Moore AS; Oncology/Haematology Service, Royal Children's Hospital, Brisbane, QLD.
Med J Aust ; 190(3): 121-5, 2009 Feb 02.
Article em En | MEDLINE | ID: mdl-19203307
ABSTRACT

OBJECTIVE:

To document haemopoietic stem cell transplantation (HSCT) activity and trends among paediatric patients in Australia and New Zealand. DESIGN, SETTING AND

PARTICIPANTS:

A retrospective analysis of data reported to the Australasian Bone Marrow Transplant Recipient Registry by the seven paediatric HSCT institutions in Australia and New Zealand over the 9-year period 1998-2006, with particular focus on the most recent years (2002-2006). MAIN OUTCOME

MEASURES:

Types of HSCT performed; transplant-related mortality (TRM); stem cell sources; indications for HSCT; causes of death after HSCT.

RESULTS:

Over the period 1998-2006, 522 autologous HSCT procedures (41%) and 737 allogeneic procedures (59%) were performed. About 60% of allogeneic transplants involved alternative donors (donors other than a human leukocyte antigen-matched sibling). The use of umbilical cord blood as a source of haemopoietic stem cells has doubled since 1998, with 34% of allogeneic transplants in 2006 using cord blood. Over the period 2002-2006, the median age of patients receiving transplants was 7 years (range, 0-19 years). The most common indications for allogeneic HSCT were acute lymphoblastic leukaemia (33%) and acute myeloid leukaemia (24%). The most common indications for autologous HSCT were neuroblastoma (23%), medulloblastoma (21%) and Ewing sarcoma (10%). TRM at 1 year after transplant was 22% for alternative donor transplants, 7% for matched-sibling transplants and 5% for autologous transplants. Relapse or persistence of a child's underlying condition accounted for 54% of all deaths within 1 year after transplant.

CONCLUSIONS:

HSCT is an important procedure for children with a range of life-threatening illnesses. Local trends in the indications for HSCT, donor selection and TRM reflect contemporary international practice.
Assuntos
Buscar no Google
Coleções: 01-internacional Temas: Geral / Tratamento / Transplante_de_medula_ossea Base de dados: MEDLINE Assunto principal: Transplante de Medula Óssea / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Oceania Idioma: En Revista: Med J Aust Ano de publicação: 2009 Tipo de documento: Article
Buscar no Google
Coleções: 01-internacional Temas: Geral / Tratamento / Transplante_de_medula_ossea Base de dados: MEDLINE Assunto principal: Transplante de Medula Óssea / Transplante de Células-Tronco Hematopoéticas Tipo de estudo: Observational_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male / Newborn País/Região como assunto: Oceania Idioma: En Revista: Med J Aust Ano de publicação: 2009 Tipo de documento: Article